KRAS mutations have been reported to drive immune evasion in several types of cancer and evidence from both pre-clinical and clinical settings has demonstrated that KRAS inhibitors can activate pro-inflammatory cytokine signaling in cancer cells 31. The gene discussed is KRAS; the disease is cancer.